Management of Severe Checkpoint Inhibitor-Related Myasthenia Gravis with Myocarditis
This patient requires consideration of additional immunosuppressive therapy beyond current corticosteroids and pyridostigmine, specifically rituximab or IVIG, given the persistent profound weakness despite completing plasmapheresis and high-dose steroids. 1
Current Clinical Status Assessment
This patient presents with Grade 3-4 immune checkpoint inhibitor-induced myasthenia gravis with concurrent myocarditis (resolved cardiac manifestations). The severity is evidenced by:
- Complete ptosis bilaterally
- Persistent dysphagia requiring tube feeds
- Inability to sit unsupported or stand
- Prior myocarditis requiring temporary pacing (now resolved)
The patient has already received appropriate acute management per ASCO guidelines: pembrolizumab permanently discontinued, plasmapheresis (6 sessions), high-dose methylprednisolone pulse therapy, and is currently on prednisone 60 mg daily with pyridostigmine 30 mg three times daily 1, 2.
Recommended Further Management
Immediate Considerations (Next 1-2 Weeks)
1. Optimize Pyridostigmine Dosing
- Current dose of 30 mg three times daily is at the lower end of the therapeutic range
- Gradually increase to 60 mg four times daily (maximum 120 mg four times daily) based on clinical response and tolerability 1, 2
- Monitor for cholinergic side effects (excessive salivation, diarrhea, abdominal cramping)
2. Consider Additional Immunosuppression
- Strongly consider rituximab given refractory symptoms despite plasmapheresis 1
- The 2021 ASCO guideline specifically recommends rituximab for patients refractory to IVIG or plasmapheresis
- Alternative: Repeat course of IVIG (2 g/kg over 5 days) if rituximab contraindicated 1, 2
3. Corticosteroid Management
- Continue prednisone 60 mg daily for at least 3-4 weeks from initiation before beginning taper 1
- Do not taper prednisone yet - the patient is only recently post-acute treatment and remains severely symptomatic
- When tapering begins, reduce very slowly (10% reduction every 1-2 weeks) based on clinical improvement
Critical Medication Review
IMMEDIATELY DISCONTINUE OR MODIFY:
Amiodarone 200 mg twice daily - This is a critical contraindication in myasthenia gravis. The FDA label for prednisone explicitly warns that concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in myasthenia gravis patients 3. While this refers to anticholinesterases, the ASCO guidelines specifically list medications that worsen myasthenia 1, 2:
- Beta-blockers (not currently on these)
- IV magnesium (not applicable)
- Fluoroquinolones (avoid for any infection)
- Aminoglycosides (avoid for any infection)
- Macrolide antibiotics (avoid for any infection)
Note: While amiodarone is not specifically listed in the ASCO guidelines, many antiarrhythmics can worsen neuromuscular transmission. Consult cardiology urgently for alternative atrial fibrillation management (consider rate control with digoxin or cardioversion if rhythm control needed).
Ongoing Monitoring Requirements
Daily assessments:
- Neurologic examination focusing on bulbar function, respiratory muscle strength, and limb strength
- Pulmonary function testing with negative inspiratory force (NIF) and vital capacity (VC) at minimum twice weekly, more frequently if any respiratory symptoms 1, 2
- Cardiac monitoring: ECG and troponin twice weekly given history of myocarditis 1
Weekly laboratory monitoring:
- Creatine kinase (CPK) - to monitor for concurrent myositis
- Troponin - to detect myocarditis recurrence
- Complete metabolic panel - monitor for steroid-related complications
Rehabilitation and Supportive Care
Intensive physiotherapy:
- Continue and intensify physical therapy as tolerated
- Focus on preventing contractures and maintaining range of motion
- Gradual progression as strength improves
Nutritional support:
- Continue tube feeds until swallowing function improves
- Formal swallowing evaluation by speech therapy before oral intake
- Monitor for aspiration risk given persistent dysphagia
Prophylaxis on high-dose steroids:
- Pneumocystis jirovecii pneumonia prophylaxis (trimethoprim-sulfamethoxazole or alternative)
- Gastric protection (already on appropriate regimen likely)
- Calcium and vitamin D supplementation
- Consider bisphosphonate for osteoporosis prevention given prolonged high-dose steroid use
Prognosis and Long-Term Considerations
Recovery timeline: ICI-associated myasthenia gravis may be monophasic, but recovery can take weeks to months 1, 2. The concurrent myocarditis (now resolved) and severity of presentation suggest this patient may require 3-6 months of immunosuppression with very slow steroid taper.
Pembrolizumab rechallenge: Absolutely contraindicated - permanent discontinuation is mandatory for Grade 3-4 neurologic immune-related adverse events 1, 2.
Steroid-induced complications: The FDA label warns that acute myopathy can occur with high-dose corticosteroids, particularly in patients with neuromuscular transmission disorders like myasthenia gravis 3. Monitor for paradoxical worsening or new proximal weakness that could indicate steroid myopathy (recent case reports document this complication 4).
Key Pitfalls to Avoid
- Premature steroid taper - maintain high-dose steroids for minimum 3-4 weeks before initiating taper 1
- Inadequate respiratory monitoring - these patients can deteriorate rapidly; maintain low threshold for ICU transfer
- Missing medication interactions - review all medications for myasthenia-worsening effects
- Underestimating recovery time - functional recovery may require months; set realistic expectations
- Overlooking concurrent myositis - elevated CPK should prompt consideration of additional immunosuppression